Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Aug;48(8):771–774. doi: 10.1136/jcp.48.8.771

Serum glutathione S-transferase B1 activity as an index of liver function in cystic fibrosis.

J M Rattenbury 1, C J Taylor 1, P K Heath 1, A F Howie 1, G J Beckett 1
PMCID: PMC502808  PMID: 7560208

Abstract

AIMS--To evaluate serum glutathione S-transferase B1 (GST B1), a highly sensitive test of hepatocellular function, as a means of identifying liver disease in patients with cystic fibrosis (CF). METHODS--The presence of liver disease was sought over a three year period in 60 children with CF, using a combination of clinical assessment, ultrasound examination, conventional biochemical tests of liver function (LFTs), and measurement of GST B1. RESULTS--Reference ranges for serum GST B1 were established in a paediatric control population. The 95% value (4.55 micrograms/l) was similar to the upper limit of normal previously derived in adults. Mean (SE) serum GST B1 activities were higher in the CF population (9.0 (1.14) micrograms/l) than in age matched controls (2.4 (0.15) micrograms/l). Ten patients with CF showed clinical signs of liver dysfunction. All but one had a serum GST B1 > 4.55 micrograms/l. Twelve other patients had elevated LFTs without clinically evident liver dysfunction, six had abnormal ultrasound scans and two showed both of these anomalies. Thirty patients with CF had neither biochemical, ultrasonographic nor clinical signs of liver disease. On review three years later, clinically important liver disease was reaffirmed in eight of the 10 index cases and had become apparent in a further eight, all of whom had elevated GST B1 activities. Five (36%) of the patients with elevated LFTs and two (33%) with isolated ultrasound changes continued to show these abnormalities. CONCLUSIONS--The limitations of conventional LFTs and ultrasound scans were evident from this study. The results suggest that elevated GST B1 activities may be a better predictor of hepatic dysfunction in CF than conventional LFTs.

Full text

PDF
771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckett G. J., Hayes J. D. Development of specific radioimmunoassays for the measurement of human hepatic basic and N/A2b glutathione S-transferases. Clin Chim Acta. 1984 Aug 31;141(2-3):267–273. doi: 10.1016/0009-8981(84)90020-2. [DOI] [PubMed] [Google Scholar]
  2. Beckett G. J., Hussey A. J., Laing I., Howie A. F., Hayes J. D., Strange R. C., Faulder C. G., Hume R. Measurements of glutathione S-transferase B1 in plasma after birth asphyxia: an early indication of hepatocellular damage. Clin Chem. 1989 Jun;35(6):995–999. [PubMed] [Google Scholar]
  3. Bolondi L., Gandolfi L., Arienti V., Caletti G. C., Corcioni E., Gasbarrini G., Labò G. Ultrasonography in the diagnosis of portal hypertension: diminished response of portal vessels to respiration. Radiology. 1982 Jan;142(1):167–172. doi: 10.1148/radiology.142.1.7053528. [DOI] [PubMed] [Google Scholar]
  4. Colombo C., Castellani M. R., Balistreri W. F., Seregni E., Assaisso M. L., Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992 Apr;15(4):677–684. doi: 10.1002/hep.1840150421. [DOI] [PubMed] [Google Scholar]
  5. Colombo C., Crosignani A., Assaisso M., Battezzati P. M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K. D. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992 Oct;16(4):924–930. doi: 10.1002/hep.1840160412. [DOI] [PubMed] [Google Scholar]
  6. Feigelson J., Anagnostopoulos C., Poquet M., Pecau Y., Munck A., Navarro J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch Dis Child. 1993 May;68(5):653–657. doi: 10.1136/adc.68.5.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galabert C., Montet J. C., Lengrand D., Lecuire A., Sotta C., Figarella C., Chazalette J. P. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr. 1992 Jul;121(1):138–141. doi: 10.1016/s0022-3476(05)82561-2. [DOI] [PubMed] [Google Scholar]
  8. Gosink B. B., Lemon S. K., Scheible W., Leopold G. R. Accuracy of ultrasonography in diagnosis of hepatocellular disease. AJR Am J Roentgenol. 1979 Jul;133(1):19–23. doi: 10.2214/ajr.133.1.19. [DOI] [PubMed] [Google Scholar]
  9. Graham N., Manhire A. R., Stead R. J., Lees W. R., Hodson M. E., Batten J. C. Cystic fibrosis: ultrasonographic findings in the pancreas and hepatobiliary system correlated with clinical data and pathology. Clin Radiol. 1985 Mar;36(2):199–203. doi: 10.1016/s0009-9260(85)80120-3. [DOI] [PubMed] [Google Scholar]
  10. Hayes P. C., Bouchier I. A., Beckett G. J. Glutathione S-transferase in humans in health and disease. Gut. 1991 Jul;32(7):813–818. doi: 10.1136/gut.32.7.813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Henderson A. R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem. 1993 Nov;30(Pt 6):521–539. doi: 10.1177/000456329303000601. [DOI] [PubMed] [Google Scholar]
  12. Isenberg J. N. Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism. Semin Liver Dis. 1982 Nov;2(4):302–313. doi: 10.1055/s-2008-1040717. [DOI] [PubMed] [Google Scholar]
  13. Kumari-Subaiya S., Gorvoy J., Phillips G., Ross P., Riddelsberger M. M. Portal vein measurement by ultrasonography in patients with long-standing cystic fibrosis: preliminary observations. J Pediatr Gastroenterol Nutr. 1987 Jan-Feb;6(1):71–78. doi: 10.1097/00005176-198701000-00013. [DOI] [PubMed] [Google Scholar]
  14. Nagel R. A., Westaby D., Javaid A., Kavani J., Meire H. B., Lombard M. G., Wise A., Williams R., Hodson M. E. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet. 1989 Dec 16;2(8677):1422–1425. doi: 10.1016/s0140-6736(89)92035-7. [DOI] [PubMed] [Google Scholar]
  15. Oppenheimer E. H., Esterly J. R. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr. 1975 May;86(5):683–689. doi: 10.1016/s0022-3476(75)80351-9. [DOI] [PubMed] [Google Scholar]
  16. Roy C. C., Weber A. M., Morin C. L., Lepage G., Brisson G., Yousef I., Lasalle R. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr. 1982;1(4):469–478. doi: 10.1097/00005176-198212000-00005. [DOI] [PubMed] [Google Scholar]
  17. Schoenau E., Boeswald W., Wanner R., Herzog K. H., Boewing B., Boehles H. J., Stehr K. High-molecular-mass ("biliary") isoenzyme of alkaline phosphatase and the diagnosis of liver dysfunction in cystic fibrosis. Clin Chem. 1989 Sep;35(9):1888–1890. [PubMed] [Google Scholar]
  18. Scott-Jupp R., Lama M., Tanner M. S. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991 Jun;66(6):698–701. doi: 10.1136/adc.66.6.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tanner M. S. Current clinical management of hepatic problems in cystic fibrosis. J R Soc Med. 1986;79 (Suppl 12):38–43. [PMC free article] [PubMed] [Google Scholar]
  20. Wilson-Sharp R. C., Irving H. C., Brown R. C., Chalmers D. M., Littlewood J. M. Ultrasonography of the pancreas, liver, and biliary system in cystic fibrosis. Arch Dis Child. 1984 Oct;59(10):923–926. doi: 10.1136/adc.59.10.923. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES